SNPs, single nucleotide polymorphisms, are genetic variations between individuals and are important factors in determining disease susceptibility and individual response to medication. Financial terms were not disclosed. Incyte has developed a comprehensive SNP platform that will aid researchers at Abbott in understanding the genetic differences between individuals and how these differences can affect disease susceptibility and drug response.
Researchers are particularly interested in SNPs that occur within genes.
These SNPs code for amino acid changes thereby altering the genes function and its production of proteins. SNPs that are located within genes are more likely to have functional consequences and are particularly useful to researchers in understanding the genetic variations between individuals. Abbott's expansion demonstrates the potential importance of SNPs in the faster development of safer, more effective drugs. Incyte Genomics, Inc. is a leading provider of an integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease. Incyte develops and markets genomic databases, genomic data management software, microarray-based gene expression services, related reagents and services.